THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF
Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
1 . A therapeutic composition comprising at least one harmine component and at least one isovanillin component, where said components are different, said at least one harmine component is selected from the group consisting of harmine, harmaline, harmane, hamalol, harmol, norharmane, 6-methoxyharmalan, bromo harmine, 2-methyl harmine, 4,9-dihydro-3H-beta-carbolin-1-yl methyl ether, 1-(4-nitrophenyl)-2,3,4,9-tetrahydro-1H-beta-carboline hydrochloride, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole {THbC}, 1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acid, 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole, 3-hydroxymethyl-b-carboline, 2,3,4,5-tetrahydro-8-methoxy-1H-pyrido[4,3-b]indole, 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-1-carboxylic acid, ethyl b-carboline-3-carboxylate, and mixtures thereof, and said at least one isovanillin component is selected from the group consisting of isovanillin, orthovanillin, isovanillyl alcohol, isovanillic acid, 2-bromo-3-hydroxy-4-methoxy benzaldehyde, 2-iodo-3-hyroxy-4-methoxy benzaldehyde, o-anisaldehyde, isovanillin oxime, ethyl vanillin, vanillin isobutyrate, veratraldehyde, 5-nitrovanillin, vanillin acetate, 3-benzyloxy-4-methoxybenzaldehyde, 3-hydroxy-5-methoxybenzaldehyde, methyl isovanillate, acetovanillone (apocynin), 2-hydroxy-4-methoxybenzaldehyde, trans-ferulic acid, 3-hydroxy-4-methoxycinnamic acid, caffeic acid, and mixtures thereof.
2 . The composition of claim 1 , comprising harmine and at least one isovanillin component selected from the group consisting of isovanillin, orthovanillin, isovanillyl alcohol, isovanillic acid, 2-bromo-3-hydroxy-4-methoxy benzaldehyde, 2-iodo-3-hyroxy-4-methoxy benzaldehyde, o-anisaldehyde, isovanillin oxime, ethyl vanillin, vanillin isobutyrate, veratraldehyde, 5-nitrovanillin, vanillin acetate, 3-benzyloxy-4-methoxybenz aldehyde, 3-hydroxy-5-methoxybenz aldehyde, methyl isovanillate, acetovanillone (apocynin), 2-hydroxy-4-methoxybenzaldehyde, trans-ferulic acid, 3-hydroxy-4-methoxycinnamic acid, caffeic acid, and mixtures thereof.
3 . The composition of claim 1 , comprising isovanillin and at least one harmine component selected from the group consisting of harmine, harmaline, harmane, hamalol, harmol, norharmane, 6-methoxyharmalan, bromo harmine, 2-methyl harmine, 4,9-dihydro-3H-beta-carbolin-1-yl methyl ether, 1-(4-nitrophenyl)-2,3,4,9-tetrahydro-1H-beta-carboline hydrochloride, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole {THbC}, 1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acid, 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole, 3-hydroxymethyl-b-carboline, 2,3,4,5-tetrahydro-8-methoxy-1H-pyrido[4,3-b]indole, 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-1-carboxylic acid, ethyl b-carboline-3-carboxylate, and mixtures thereof.
4 . The composition of claim 1 , wherein both of said at least one components are individually and independently in the form of esters, metal complexes, pharmaceutically acceptable salts, and mixtures thereof.
5 . The composition of claim 1 , said composition consisting essentially of both of said at least one components.
6 . The composition of claim 1 , said composition exhibiting anti-cancer synergy.
7 . The composition of claim 6 , said composition exhibiting anti-cancer synergy against lung cancer cells, lymphoma cells, and leukemia cells.
8 . The composition of claim 7 , said composition exhibiting anti-cancer synergy against lung cancer cells, H358, lymphoma cells, MO205, and leukemia cells, jurkat E6-1.
9 . The composition of claim 1 , wherein said at least one isovanillin component is present at a level greater than that of said at least one harmine component.
10 . The composition of claim 1 , said composition being an anti-cancer composition for administration to a cancer patient.
11 . The composition of claim 1 , the weight ratio of said isovanillin component(s) to said harmine component(s) ranging from about 0.5:1 to 15:1.
12 . The composition of claim 1 , said isovanillin component(s) being present at a level of from about 25-95% by weight, and said harmine component(s) being present at a level of from about 5-75% by weight.
13 . The composition of claim 1 , wherein said harmine component comprises harmaline, and said isovanillin component comprises vanillin. (562)
14 . The composition of claim 13 , wherein said composition consists essentially of harmaline and vanillin. (562)
15 . The composition of claim 1 , wherein said harmine component comprises harmaline and said isovanillin component comprises a compound of the structure (560)
where Q9 is a C1 aldehyde, and Q10 and Q11 are both H.
16 . The composition of claim 15 , wherein said composition consists essentially of harmaline and the isovanillin component of claim 15 .
17 . The composition of claim 1 , wherein said harmine component comprises harmaline and said isovanillin component comprises a compound of the structure (561)
where Q9 is a C3 aldehyde, and Q10 and Q11 are both H.
18 . The composition of claim 17 , wherein said composition consists essentially of harmaline and the isovanillin component of claim 17 .
19 . A method of treating a human patient suffering from cancer comprising the step of administering to the patient a composition in accordance with claim 1 .
20 . A method of killing or inhibiting the growth of cancer stem cells comprising the step of administering to a patient a composition in accordance with claim 1 .
21 . A therapeutic composition comprising the combination of at least one curcumin component, at least one harmine component, and at least one isovanillin component, wherein the components of the composition are different.
22 . The composition of claim 21 , said at least one isovanillin component selected from the group consisting of compounds of the formula
wherein Q1 is an aldehyde, alcohol, amine, carbonyl, carboxylate, C1-C6 alkylhydroxy, ester, imidazole, or semicarbazone group; the Q2-Q6 groups are independently selected from hydrogen, hydroxyl, halo, sulfonate, sulfoxide, thio, ester, carboxylate, amide, oxime, or borate, nitro, C1-C6 alkoxy, and C1-C6 alkyl or alkenyl groups, with the proviso that at least one of the Q2-Q6 groups is an alkoxy group.
23 . The composition of claim 22 , at least one of the Q2-Q6 groups is an alkoxy group, and another is a hydroxyl group.
24 . The composition of claim 21 said at least one isovanillin component having the formula
where the two * denote valence points where the terminal portions of the components are attached, the remaining phenyl ring positions are independently selected from the group consisting of H, hydroxyl, halogen, amine, nitro, sulfonate, sulfoxide, thio, ester, carboxylate, amide, borate, C1-C4 boronate, C1-C8 alkyl, C2-C8 alkenyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 amine, C2-C8 carboxyl, C2-C8 ester, C1-C4 aldehyde, and glucuronide groups, and Q7 is H or a C1-C6 alkyl group.
25 . The composition of claim 21 said at least one isovanillin component having the formula
where Q9 is selected from the group consisting of C1-C4 aldehydes, C1-C4 alkylalcohols, C1-C4 alkyl esters, and C1-C4 organic acids, Q10 is selected from the group consisting of OH, H, C1-C6 alkyl esters, C1-C4 alkoxys, and benzyloxy, and Q11 is selected from the group consisting of H, C1-C4 alkoxys, and OH.
26 . The composition of claim 21 said harmine component selected from the group consisting of compounds of the formulas
wherein:
Z1 is hydrogen; a C1-C6 alkyl or haloalkyl, a C2-C6 alkenyl or haloalkenyl; an aryl group or an arylalkyl group, wherein the aryl group is optionally substituted at any position with halogen, nitro, hydroxyl, C1-C3 alkoxy, amino, sulfonate, sulfoxide, thio, ester, carboxylate, amide, borate, or C1-C4 boronate and wherein the alkyl group is selected from C1-C4 alkyl; or a heterocyclic group;
Z2 is hydrogen; a C1-C6 carboxyl, ester, carboxylate, acylamino, acyl halide, sulfonate, sulfoxide, thio, amide or alkoxycarbonyl group; an aryloxycarbonyl group; alkyl group optionally substituted with hydroxyl or alkoxycarbonyl; carbamate; acylhydrazine; or a heterocyclic oxycarbonyl group, where the heterocyclic portion contains from 3-7 atoms and a nitrogen, oxygen, boron, or sulfur heteroatom;
Z3 is hydrogen; a C1-C6 alkyl or haloalkyl; sulfonate, sulfoxide, thio, carboxylate, amide, C2-C6 alkenyl group; hydroxyl; a C1-C6 alkoxy group; a C1-C6 carboxylic ester group; an arylalkoxy group where the alkoxy portion contains from 1-6 carbon atoms; or a heterocyclic group containing from 3-7 atoms and a nitrogen, oxygen, boron, or sulfur heteroatom;
Z4 is hydrogen; a C1-C6 alkyl, haloalkyl; C2-C6 alkenyl group; a hydroxyalkyl group where the alkyl portion contains from 1-6 carbon atoms; an arylalkyl group wherein the aryl group is optionally substituted at any position with halogen, nitro, hydroxyl, C1-C3 alkoxy, borate, C1-C4 boronate, sulfonate, sulfoxide, thio, ester, carboxylate, amide or amino, and wherein the alkyl group is selected from C1-C4 alkyl group; an arylalkanone; or a heterocyclic group containing from 3-7 atoms and a nitrogen, oxygen, boron or sulfur heteroatom;
Z5 is hydrogen; a C1-C6 alkyl group; an aryl group substituted at any position with one or more of (1)-(2), where (1) is a C1-C4 alkyl group, and (2) is a C1-C6 carbonyl, hydroxycarbonyl, ester, sulfonate, sulfoxide, thio, ester, carboxylate, amide or amino group; arylalkyl where the alkyl group is a C1-C6 alkyl; 1-5 substituted arylalkyl; arylhydrocarbyl; arylcarboxyl; aryl ester group; arylamino group; or a heterocyclic group containing from 3-7 atoms and a nitrogen, oxygen, boron or sulfur heteroatom;
X is a halogen; a sulfonic group, a sulfuric group, a nitric acid group or a carboxylate, in the compounds of the formulas set forth in this claim.
27 . The composition of claim 26 , wherein said at least one harmine component is selected from the group consisting of compounds of the formula
where the three * denote valence points where the terminal portions of the components are attached; Z1 and Z4 are independently H or a C1-C6 alkyl group; and the remaining positions on the phenyl rings are each independently Z1.
28 . The compositions of claim 21 , wherein said composition exhibits therapeutic synergy.
29 . The composition of claim 28 , said composition exhibiting anti-cancer synergy against lung cancer cells, lymphoma cells, and leukemia cells.
30 . The composition of claim 29 , said composition exhibiting anti-cancer synergy against lung cancer cells, H358, lymphoma cells, MO205, and leukemia cells, jurkat E6-1.
31 . The composition of claim 21 , wherein said at least one isovanillin component is present at a level greater than that of said at least one harmine component.
32 . The composition of claim 21 , the weight ratio of said isovanillin component(s) to said harmine component(s) ranging from about 0.5:1 to 15:1.
33 . The composition of claim 21 , said isovanillin component(s) being present at a level of from about 25-95% by weight, and said harmine component(s) being present at a level of from about 5-75% by weight.
34 . The composition of claim 21 , wherein said components are individually and independently in the form of esters, metal complexes, pharmaceutically acceptable salts, and mixtures thereof.
35 . The composition of claim 21 , said composition being an anti-cancer composition for administration to a cancer patient.
36 . A method of treating a human patient suffering from cancer comprising the step of administering to the patient a composition in accordance with claim 21 .
37 . A method of killing or inhibiting the growth of cancer stem cells comprising the step of administering to a patient a composition in accordance with claim 21 .
38 . A method of making a therapeutic composition comprising the steps of mixing together at least one harmine component and at least one isovanillin component.
39 . The method of claim 38 , wherein said at least one isovanillin component is present at a level greater than that of said at least one harmine component.
40 . The method of claim 38 , the weight ratio of said isovanillin component(s) to said harmine component(s) ranging from about 0.5:1 to 15:1.
41 . The method of claim 38 , said isovanillin component(s) being present at a level of from about 25-95% by weight, and said harmine component(s) being present at a level of from about 5-75% by weight.
42 . The method of claim 38 , wherein said components are individually and independently in the form of esters, metal complexes, pharmaceutically acceptable salts, and mixtures thereof.
43 . A product prepared by the method of claim 38 .